Inovio Pharmaceuticals, Inc. Overview
Pro stress-test →Inovio is a clinical-stage biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company develops DNA medicine, a type of therapy that gives patients' bodies the blueprint to produce specific immune responses to fight diseases. The company is pursuing regulatory approval for its lead candidate targeting a rare respiratory disease with significant unmet medical need.
Strategic Profile
Pro stress-test →Inovio sought to develop and market a coronavirus vaccine in the early years of the pandemic, though efforts were unsuccessful and the stock has lost significant market value. The FDA has accepted Inovio's biologics license application (BLA) for INO-3107 for review under the Accelerated Approval Program, with a PDUFA target date of October 30. The company's DNA platform represents its core competitive advantage, though commercialization faces challenges related to the proprietary Cellectra device delivery mechanism.
Competitive Landscape
Pro stress-test →Inovio competes in the immunotherapy and DNA medicine space against larger biotech and pharma companies. A competing product was approved last year to treat RRP, though Inovio believes significant unmet need remains as the competitor does not work for all patients. The company's proprietary DNA platform and Cellectra delivery system differentiate it but also create execution risk.
Industry Context
Inovio Pharmaceuticals, Inc. operates in Biopharmaceuticals / Clinical Stage Biotech.
Key facts
Founded: 1983 · Headquarters: Plymouth Meeting, Pennsylvania, United States